Canagliflozin (CANA) added on to dipeptidyl peptidase-4 inhibitors (DPP-4I) or glucagon-like peptide-1 (GLP-1) agonists with or without other antihyperglycemic agents (AHAS) in type 2 diabetes mellitus (T2DM)

  • Woo V
  • Wysham C
  • Mathieu C
 et al. 
  • 16

    Readers

    Mendeley users who have this article in their library.
  • N/A

    Citations

    Citations of this article.

Abstract

Purpose: Evaluate the efficacy and safety of CANA 100 mg and 300 mg compared with placebo (PBO) as add on to incretin-based therapy. Methods: Post-hoc analyses of data from the CANagliflozin cardioVascular Assessment Study (CANVAS) evaluated CANA 100 mg and 300 mg vs. PBO in subsets of subjects on DPP-4i (n=316; mean age 63 years; A1C 8.1%; BMI 32.3) or GLP-1 agonists (n=95; mean age 61 years; A1C 8.1%; BMI 37.4) as monotherapy or in combination with other AHAs. Results: At week 18, CANA 100 and 300 mg reduced A1C and weight relative to PBO in both subsets (Table). Adverse event (AE) rates were higher with CANA than with PBO in the DPP-4i subset, comparable or lower with CANA relative to PBO in the GLP-1 agonist subset; serious AE rates were generally higher with CANA than PBO in both subsets. Documented hypoglycemia rates were higher with CANA 100 mg and 300 mg than PBO in subjects on insulin, sulfonylurea or meglitinide in the DPP-4i subset (17/70, 29/87 and 12/74) and the GLP-1 agonist subset (11/29, 11/22 and 4/26); only 2 and 1 CANA-treated subjects not on these concomitant agents reported hypoglycemia in the DPP-4i and GLP-1 agonist subsets, respectively. Summary: In these post-hoc analyses, CANA added on to DPP-4i or GLP-1 agonists(+/e other AHAs) lowered A1C, reduced body weight and was generally well tolerated in subjects with T2DM at 18 weeks. (Table Presented) .

Author-supplied keywords

  • agonist
  • body weight
  • canagliflozin
  • diabetes mellitus
  • dipeptidyl peptidase IV inhibitor
  • endocrinology
  • glucagon like peptide 1
  • glucagon like peptide 1 receptor agonist
  • human
  • hypoglycemia
  • incretin
  • insulin
  • meglitinide
  • metabolism
  • monotherapy
  • non insulin dependent diabetes mellitus
  • placebo
  • post hoc analysis
  • safety
  • society
  • sulfonylurea
  • therapy
  • weight

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Authors

  • V Woo

  • C Wysham

  • C Mathieu

  • M Desai

  • M Alba

  • G Capuano

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free